Tag: SCS

Nevro announces clinical data reinforcing significant and durable benefits of 10kHz...

Nevro Corporation has announced the results from data presentations at the 25th North American Neuromodulation Society (NANS) annual meeting (13–15 January 2022; Orlando, USA) supporting...

DTM spinal cord stimulation endurance therapy associated with meaningful pain relief...

Differential Target Multiplexed (DTM) spinal cord stimulation (SCS) endurance therapy provides meaningful pain relief according to three-month data from the DTM-LE trial—the findings of...
spinal cord stimulation patient access

Current gaps and barriers in patient access to spinal cord stimulation

Maricela Schnur (St Luke’s Hospital, Duluth, USA) highlights a handful of socioeconomic disparities, racial differences, and psychological and psychiatric factors, that currently present difficulties...

Passive recharge burst spinal cord stimulation provides sustainable improvements in pain...

Passive recharge burst spinal cord stimulation (B-SCS) can alleviate pain intensity, psychological distress, and improve physical function and health-related quality of life out to two years,...
scs diabetic neuropathy

High-frequency SCS takes the stage to relieve chronic pain from diabetic...

Following the recent approval of the Senza system (Nevro) by the US Food and Drug Administration (FDA), Erika A Petersen (Little Rock, USA) discusses the...

NeoSpine first to offer spinal cord stimulation for treatment of painful...

NeoSpine is now offering spinal cord stimulation (SCS) procedures for the treatment of painful diabetic neuropathy (PDN) via its HFX system—a newly approved nondrug treatment...
nevro senza

Nevro announces FDA approval of high-frequency SCS therapy for painful diabetic...

Nevro has announced receipt of US Food and Drug Administration (FDA) approval for its Senza system to treat chronic pain associated with painful diabetic...

Medtronic receives FDA approval for labelling of Intellis platform when using...

Medtronic has announced that the US Food and Drug Administration (FDA) has approved the revised commercial labelling for the Intellis platform with differential target...

Non-surgical refractory back pain patients have better pain outcomes with 10KhZ...

Findings of a randomised, prospective study suggest that non-surgical refractory back pain (NSRBP) patients have better outcomes with 10KhZ spinal cord stimulation (SCS) and...

Abbott launches NeuroSphere myPath digital health app 

Abbott has announced the launch of its NeuroSphere myPath digital health app, designed to track and report patient perceived pain relief and general well-being...

WaveWriter Alpha SCS systems launches in USA

Boston Scientific has announced that its WaveWriter Alpha spinal cord stimulation (SCS) systems will have a limited market release in the USA. The SCS...

New findings suggest patients prefer one-stage SCS screening trial

A new study, published in the journal Neuromodulation, has found that patients show a preference for a one-stage spinal cord stimulation (SCS) screening trial,...